—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Charles River Laboratories (CRL) — chart, structure and Closelooknet read

The Closelooknet read

Charles River Laboratories provides drug discovery, non-clinical development, and safety testing services to pharmaceutical and biotech developers worldwide. It breeds and sells research rodents, runs in vitro and in vivo testing for new drug candidates, and offers manufacturing and quality-control testing for biologics.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Research diary readings, not advice.

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for CRL, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 47/100 · S&P 500 fund at 48, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-06
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 60th percentile of the window, -22.8% over 20 sessions. Factor regime → 2026-11-06
  • Sovereign pressure Index -1.91 · down 2.45 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-11-06
How it trades on rate days beta 0.64 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How CRL has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.64 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Charles River Laboratories moved 0.64% on average · correlation 0.13 · higher than 57% of US names
  • Beta, last 3 months −0.36 less rate-sensitive lately than over the year
  • On the 10 worst bond days −0.60% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +6.17% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Diagnostics & Research · United States · 8 names with week and year-to-date

Peer group

Diagnostics & Research · United States

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against CRL on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Charles River Laboratories

CRL in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Charles River Laboratories provides drug discovery, non-clinical development, and safety testing services to pharmaceutical and biotech developers worldwide. It breeds and sells research rodents, runs in vitro and in vivo testing for new drug candidates, and offers manufacturing and quality-control testing for biologics. Its clients range from early discovery labs to companies preparing therapies for regulatory review. It is headquartered in Wilmington, United States, and trades on a US exchange.
Where it sits in the stack
Charles River sits outside Rubin, our AI build-out index; it belongs instead to the diary's healthcare and life-sciences universe, where it acts as a testing and research-services provider that drug developers rely on to move compounds through non-clinical stages before trials begin.
Who it is priced against
Closelooknet's peer group has not been set for this name; the company most often named alongside it is IQVIA, another contract research organisation serving drug developers through the clinical pipeline.
Why Closelooknet tracks it
It sits in the S&P 500; Closelooknet has not yet built a score for it, so its module read is still being assembled as coverage widens.
What the diary watches
Whether biotech funding cycles lift or slow demand for outsourced testing and research-model work, since that flow feeds directly into the segments Charles River reports.

Charles River Laboratories (CRL) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 5 analyst actions on the wire · latest: price target by Jefferies, 2026-09-28

The Street on this name

Analyst actions and the latest print for CRL from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Jefferies — target 340 Target set to $340 (+16.1% to spot) 2026-09-28
  • Price target Deutsche Bank — target 320 from 300 Target raised to $320 from $300 (+9.9% to spot) 2026-09-25
  • Price target RBC Capital — target 322 from 282 Target raised to $322 from $282 (+10.6% to spot) 2026-09-25

5 actions on the analyst wire since 2026-08-13: 5 target changes. Analyst wire → · Earnings wire →

FAQ · from the current data · as of 2026-11-07

Quick answers

What is Charles River Laboratories (CRL)?

Charles River Laboratories trades as CRL on the US exchange (United States) in the Closelooknet research universe, as of the registry build of 2026-11-07.

Is CRL in a Closelooknet index?

Not currently — Charles River Laboratories is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-11-07.

Where does CRL trade against its moving averages?

Charles River Laboratories trades 10.4% above its 50-day and 50.3% above its 200-day moving average (1.5% above its 20-day). As of 2026-11-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Charles River Laboratories compare with its peers?

Against its peer group (Diagnostics & Research · United States), Charles River Laboratories (CRL) sits 11.1% below its 52-week high, 10.4% above its 50-day average; Mettler-Toledo International Inc (MTD) is 4.7% below, Labcorp Holdings Inc. (LH) is 1.8% below, Qiagen NV (QGEN) is 13.0% below, as of 2026-11-06. Put any of them next to CRL in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Charles River Laboratories trade when bond yields rise?

Over the past year Charles River Laboratories had a beta of 0.64 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 57% of US names. On the 10 sessions in which long bonds fell most it moved −0.60% on average, against −0.74% for the S&P 500. As of 2026-11-06; The "How it trades on rate days" block on this page carries the lines.

What does Charles River Laboratories do?

Charles River Laboratories provides drug discovery, non-clinical development, and safety testing services to pharmaceutical and biotech developers worldwide. It breeds and sells research rodents, runs in vitro and in vivo testing for new drug candidates, and offers manufacturing and quality-control testing for biologics. Its clients range from early discovery labs to companies preparing therapies for regulatory review. Closelooknet's peer group has not been set for this name; the company most often named alongside it is IQVIA, another contract research organisation serving drug developers through the clinical pipeline. (Company snapshot of 2026-09-17.)

Where does Charles River Laboratories sit in the AI build-out?

Charles River sits outside Rubin, our AI build-out index; it belongs instead to the diary's healthcare and life-sciences universe, where it acts as a testing and research-services provider that drug developers rely on to move compounds through non-clinical stages before trials begin. It sits in the S&P 500; Closelooknet has not yet built a score for it, so its module read is still being assembled as coverage widens. (Company snapshot of 2026-09-17.)

What has Wall Street done on Charles River Laboratories recently?

The most recent analyst action on Charles River Laboratories on the Closelooknet wire is a price target by Jefferies on 2026-09-28 (target 340). 5 actions on the analyst wire since 2026-08-13: 5 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for CRL, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

then Diagnostics & Research. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.